Our study proposed a possibility that the expression of PD-L1 in the glioma microenvironment is intrinsically driven by the immune system and implies that anti-PD-1/PD-L1 therapy might be preferentially beneficial for patients with high IFN-γ score. This evidence concerns the gene IFNG and glioma.